Tue, Apr 15, 8:31 PM (14 days ago)
**BioSig Technologies, Inc. (BSGM)** **Financial Performance:** - **Revenue:** $40,000 for 2024, up from $18,000 in 2023. - **Net Income:** -$10,339,000 for 2024, an improvement from -$28,690,000 in 2023. - **Operating Expenses:** $12,902,000 for 2024, down from $28,530,000 in 2023. - **Earnings Per Share:** -$0.75 for 2024, improved from -$3.95 in 2023. **Strategic Overview:** - **Product Focus:** PURE EP™ Platform for cardiac arrhythmia treatment. - **Patents:** 41 issued/allowed utility patents, 31 pending, and 30 design patents. - **Licenses:** 12 issued/allowed patents and 9 pending from Mayo Foundation. **Future Outlook:** - **Market Position:** Competitive EP market with key players like GE, Johnson & Johnson, Boston Scientific, Siemens, Medtronic, and Abbott. - **Risk Factors:** Substantial doubt about ability to continue as a going concern, reliance on additional financing, and regulatory approvals. **Market Position Changes:** - **Delisting and Relisting:** Nasdaq delisting and subsequent relisting, with ongoing compliance challenges. - **Workforce Reductions:** Significant workforce reductions and management changes in 2024. **Financial Condition:** - **Cash Position:** $142,000 as of December 31, 2024, down from $190,000 in 2023. - **Working Capital:** Deficit of $1,920,000 as of December 31, 2024. - **Debt:** Issued a promissory note for $500,000 in 2024, converted into shares and warrants. **Risk Factors:** - **Operational Risks:** Dependence on key personnel, cybersecurity risks, and regulatory compliance. - **Financial Risks:** Need for additional financing, potential dilution of shares, and market volatility. - **Legal Risks:** Ongoing litigation and potential intellectual property disputes.